Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2013-01-21
Original market date: See footnote 1
1989-12-31
Product name:
(20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP
DIN:
00437999
Product Monograph/Veterinary Labelling:
Date:
2016-04-07
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BAXTER CORPORATION
7125 Mississauga Road
Mississauga
Ontario
Canada
L5N 0C2
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
3
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
40:20.00 , 40:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
B05BB02 ELECTROLYTES WITH CARBOHYDRATES
Active ingredient group (AIG) number:See footnote5
0300097005
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| DEXTROSE | 5 G / 100 ML |
| POTASSIUM CHLORIDE | 150 MG / 100 ML |
| SODIUM CHLORIDE | 450 MG / 100 ML |